Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer.

Endocrine oncology (Bristol, England)·2026
Same author

Assessing the capability of large language models in answering pediatric critical care board-style questions.

Scientific reports·2026
Same author

Polygenic risk score with KLK3 SNP-SNP interaction pairs for predicting prostate cancer aggressiveness.

Communications medicine·2026
Same author

Germline polygenic score for prostate cancer aggressiveness.

medRxiv : the preprint server for health sciences·2026
Same author

Single-cell genomic analysis of cancer cells from one treatment-naïve patient with metastatic prostate cancer.

BMC genomic data·2026
Same author

Combining External Beam Radiotherapy and Immunotherapy for the Treatment of Hepatocellular Carcinoma.

Current oncology (Toronto, Ont.)·2026

Related Experiment Video

Updated: Jul 15, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

18F-PSMA-1007 PET/CT Demonstrates Higher Accuracy for Biochemically Recurrent Prostate Cancer Compared to

Zachary Stanton1, Bonnie Woloschuk1, Alexander Tamm1

  • 1Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada, ualberta.ca.

Advances in Urology
|July 13, 2026
PubMed
Summary

18F-PSMA-1007 PET/CT is more accurate than conventional imaging for detecting recurrent prostate cancer. This advanced imaging technique improves diagnostic accuracy and aids clinical decision-making in patients with biochemically recurrent disease.

Keywords:
CTPET/CTPSMA-1007biochemical recurrencebone scanprostate cancer

More Related Videos

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Related Experiment Videos

Last Updated: Jul 15, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Area of Science:

  • Oncology
  • Radiology
  • Nuclear Medicine

Background:

  • Biochemically recurrent prostate cancer requires accurate imaging for treatment planning.
  • Conventional imaging modalities have limitations in detecting subtle recurrence.
  • Prostate-specific membrane antigen (PSMA) targeted imaging offers a promising alternative.

Purpose of the Study:

  • To compare the diagnostic accuracy of 18F-PSMA-1007 PET/CT with conventional imaging (CT and bone scan) in patients with biochemically recurrent prostate cancer.
  • To evaluate the impact of 18F-PSMA-1007 PET/CT on clinical management decisions.

Main Methods:

  • Prospective Phase II cohort study involving 85 patients with biochemically recurrent prostate cancer.
  • 18F-PSMA-1007 PET/CT performed, followed by conventional imaging within 12 days.
  • Lesion-level and patient-level analyses conducted after a minimum 1-year follow-up.

Main Results:

  • 18F-PSMA-1007 PET/CT demonstrated higher sensitivity (100% vs. 58.3%) and accuracy (90.6% vs. 62.3%) compared to conventional imaging.
  • Referring physicians found 18F-PSMA-1007 PET/CT beneficial in 90.6% of cases.
  • Significant improvement in diagnostic performance (p < 0.05).

Conclusions:

  • 18F-PSMA-1007 PET/CT is superior to conventional imaging for evaluating biochemically recurrent prostate cancer.
  • This advanced imaging modality should be considered for routine clinical use.
  • Supports the use of 18F-PSMA-1007 PET/CT in clinical practice for improved patient care.